David Kirn
2021
In 2021, David Kirn earned a total compensation of $5.2M as Chief Executive Officer at 4D Molecular Therapeutics, a 641% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $228,000 |
|---|---|
| Option Awards | $4,389,825 |
| Salary | $570,000 |
| Other | $13,000 |
| Total | $5,200,825 |
Kirn received $4.4M in option awards, accounting for 84% of the total pay in 2021.
Kirn also received $228K in non-equity incentive plan, $570K in salary and $13K in other compensation.
Rankings
In 2021, David Kirn's compensation ranked 2,495th out of 12,412 executives tracked by ExecPay. In other words, Kirn earned more than 79.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,495 out of 12,412 | 80th |
Division Manufacturing | 991 out of 5,498 | 82nd |
Major group Chemicals And Allied Products | 379 out of 2,374 | 84th |
Industry group Drugs | 331 out of 2,095 | 84th |
Industry Biological Products, Except Diagnostic Substances | 100 out of 452 | 78th |
Source: SEC filing on April 13, 2022.
Kirn's colleagues
We found three more compensation records of executives who worked with David Kirn at 4D Molecular Therapeutics in 2021.
News
4D Molecular Therapeutics CEO David Kirn's 2023 pay jumps 213% to $10M
April 10, 2024
4D Molecular Therapeutics CEO David Kirn's 2022 pay falls 37% to $3.3M
April 12, 2023
4D Molecular Therapeutics CEO David Kirn's 2021 pay jumps 641% to $5.2M
April 13, 2022
4D Molecular Therapeutics Chief Medical Officer Robert Fishman receives $3.3M in 2020
April 6, 2021